The real-world data of the trials showed that patients experienced a 90% reduction in adverse effects associated with marijuana use in comparison with other methods such as oil, smoking, and vaping.
Eight Years And $83 Million Later, Syqe® Medical Releases First Cannabis Inhaler
Teva will market the company’s inhalers exclusively in Israel, after signing a marketing and distribution agreement with Syqe® in 2016.
